

# Cancer Genetics and Prevention: Nursing Practice and Science Implications

Meghan Underhill-Blazey, PhD, APRN, FAAN



SCHOOL OF  
NURSING  
UNIVERSITY of ROCHESTER

# Objectives


1. Synthesize patient reported experiences of living with hereditary cancer risk across multiple hereditary cancer domains.
2. Explore patient focused interventions aimed at supporting patients and families living with high risk for hereditary cancer.
3. Describe nursing focused education, practice, and research opportunities to improve the psychosocial support of individuals living with high risk for hereditary cancer.



# Program of Research

- **Goal:** Improve the experience of persons and families living with increased risk for cancer through innovative technology-based health promoting interventions.
  - What is the meaning and experience of living with cancer predisposition?
  - How do at-risk individuals and families engage in self-care?
  - How can nursing science best support at-risk individuals and families to effectively utilize cancer risk related information to promote health?
  - How can research, policy, and practice initiatives improve the experience of persons living with cancer risk?





**Why is Cancer Genetics and Prevention an important area for Nursing Practice and Nursing Science?**

INSIDE: A Day With Jimmy Carter

# TIME

The DNA Furor  
**TINKERING WITH LIFE**

SPECIAL REPORT

# TIME

**Genetics**  
THE FUTURE IS NOW

New breakthroughs can cure diseases and save lives, but how much should nature be engineered?

OCTOBER 23, 2004

# TIME

Does our DNA compel us to seek a higher power? Believe it or not, some scientists say yes  
**PLUS: A quiz—How spiritual are you?**

**THE GOD GENE**

What scientists have uncovered about **HOW MEMORY WORKS** and how to improve it

**THE I.Q. GENE?**

THE FUNDEST MAN IN AMERICA

Egypt Divided / Pat's Big Moment / Best of 2012

# TIME

Want to Know My Future?

Asthma, Diabetes, Cancer, Hemochromatosis, Crohn's disease, Cystic fibrosis, Top-Sachs disease, Breast cancer, Huntington's disease, Alzheimer's, Parkinson's, Glaucoma, Multiple sclerosis, Burkitt's lymphoma, Malignant melanoma, Prostate cancer, Obesity

New genetic tests can point to risks—but not always a cure

BY BONNIE ROCHMAN

Joe Klein: The CIA's Afghan Disaster, Yemen: The New Center Of Terror, Why the Recession Hasn't Been Cool To Teens

# TIME

**WHY YOUR DNA ISN'T YOUR DESTINY**

The new science of epigenetics reveals how the choices you make can change your genes—and those of your kids

BY JOHN CLOUD

HUMAN CLONING IS CLOSER THAN YOU THINK

For couples who can't have a child—or who have lost one—the unthinkable may soon be possible. Here are the perils

EXCLUSIVE Q&A  
DR. LAURA ON THE OFFENSIVE

**Cracking The Code!**

The inside story of how these bitter rivals mapped our DNA, the historic feat that changes medicine forever

J. Craig Venter, Francis Collins

CELERA

# Selected genetics milestones that impact practice

**1948:** Creation of the American Society of Human Genetics

**1957:** Johns Hopkins establishes the Division of Medical Genetics- Dr. Victor McKusick

**1963:** Newborn screening begins

**1966:** Prenatal screening begins

**1970:** First genetic counseling program at Sarah Lawrence College

**1990** new technology allows for pre-symptomatic genetic testing

**1990-2003:** Human genome project begins

**1993:** Huntington disease gene identified; Lynch Syndrome genes discovered

**1994:** BRCA1 discovered

**1996:** BRCA2 discovered

**2008:** GINA signed into law (Genetic Information Nondiscrimination Act)

**2008:** Genetics added to the essentials of nursing practice

**2011:** clinical exome testing developed; cell-free DNA for prenatal testing

**2012:** the first multigene cancer panels become available

**2014:** US supreme court strikes down human gene patents, allowing multiple labs to provide testing at a reduced cost

<https://www.nsgc.org/About/About-NSGC/Timeline>

**2015:** 23 & Me begins




SCHOOL OF  
**NURSING**  
UNIVERSITY of ROCHESTER

# Genetics and Cancer

- Cancer is a genetic disease
- Some genetic changes can be inherited (germline) or acquired after conception (somatic)

## Somatic mutations

- Occur in nongermline tissues
- Are nonheritable




Nonheritable

Somatic mutation  
(e.g., breast)

## Germline mutations

- Present in egg or sperm
- Are heritable
- Cause cancer family syndrome




Mutation in  
egg or sperm

All cells  
affected in  
offspring

Reprinted by permission, © 2004

# Inherited cancer risk




- We are born with many genes that are associated with cancer
  - Born with two copies
  - One from biological father and one from biological mother
  - When they are working they actually stop cancer from occurring!
- If a person is born with a copy of the gene that doesn't work, "**pathogenic variant**", cancer may occur more frequently or at a younger age
- These abnormally working genes can be passed down within families; called **inheritance**



# How common is inherited cancer risk?

- Most cancers are “sporadic”
- Inherited risk for cancer is rare, however, if a person carries an abnormal gene associated with cancer they may be at increased risk for developing cancer themselves
- Having a genetic risk for cancer is NOT a diagnosis of cancer, it is a marker for increased risk over the course of a persons lifetime.
- Family members may also have risk





# Red flags for cancer risk

- Diagnosed with cancer at age 50 or younger
- More than one primary cancer in same individual
- Multiple family members (more than 2) on the same side of the family diagnosed with cancer
- Pancreatic cancer
- Ovarian cancer
- Male breast cancer
- Breast cancer under age 45, triple negative, or metastatic
- Metastatic prostate cancer
- MMR deficient colorectal cancers



# Professional guidelines for referral: Genetic counseling and testing

- National comprehensive cancer network (NCCN)
- American Society of Clinical Oncology (ASCO)
- Oncology Nursing Society (ONS)
- American Society of Breast Surgeons (ASBS)
- American College of OBGYN (ACOG)

**Many people diagnosed with cancer are recommended cancer genetic testing and should be informed and the list is growing every day!**

# What is genetic counseling?


*"Genetic Counseling is the process of helping people understand and adapt to the medical, psychological and familial implications of genetic contributions to disease."*



# Multiple models for health care delivery



CREATED BY VECTORPORTAL.COM



# Genetic Testing

## Single Gene Testing

## Gene Panel Testing

Approaches to Genetic Testing



Hereditary Cancer Next-Gen Panels by Gene

| GENES  | BreastNext | OvaNext | ColoNext | CancerNext |
|--------|------------|---------|----------|------------|
| ATM    | •          | •       |          | •          |
| BARD1  | •          | •       |          | •          |
| BRIP1  | •          | •       |          | •          |
| MRE11A | •          | •       |          | •          |
| NBN    | •          | •       |          | •          |
| RAD50  | •          | •       |          | •          |
| RADS1C | •          | •       |          | •          |
| PALB2  | •          | •       |          | •          |
| STX3   | •          | •       |          | •          |
| CHEK2  | •          | •       | •        | •          |
| PTEN   | •          | •       | •        | •          |
| TP53   | •          | •       | •        | •          |
| CDH1   | •          | •       | •        | •          |
| MUTYH  | •          | •       | •        | •          |
| MLH1   |            | •       | •        | •          |
| MSH2   |            | •       | •        | •          |
| MSH6   |            | •       | •        | •          |
| EPCAM  |            | •       | •        | •          |
| PMS2   |            | •       | •        | •          |
| PMS1   |            | •       | •        | •          |
| APC    |            | •       | •        | •          |
| BMPRIA |            |         | •        | •          |
| SMAD4  |            |         | •        | •          |

# Multigene Cancer Panel Testing: Standard of Care

- Simultaneously test for roughly 40-80 cancer susceptibility genes (or more!) compared to syndrome or gene specific testing
- Include genes of moderate, high penetrance
- Multiple commercial panels are available – organ specific vs pan-cancer
- Panels are constantly changing



# Genetic Testing Results

- Positive
  - Medical management implications for individual and family
- Negative
  - Uninformative versus true negative
- Variant of Uncertain Significance
  - Change was found but meaning *unknown*
  - No medical management implications unless reclassified
  - 30% of all panel test results will have a VUS

CONFIDENTIAL

Integrated BRACAnalysis® with Myriad myRisk™ Hereditary Cancer

**myRisk Genetic Result**

MYRIAD myRisk™ Hereditary Cancer

Powered by

RECEIVING HEALTHCARE PROVIDER  
**Physician Name, MD**  
 Myriad Oncology Partners  
 320 Wakara Way  
 Salt Lake City, UT 84108

SPECIMEN  
 Specimen Type: Buccal  
 Draw Date: Apr 8, 2012  
 Accession Date: Apr 9, 2012  
 Report Date: Apr 30, 2012

PATIENT  
 Name: Patient Name  
 Date of Birth: Jan 12, 1950  
 Patient ID: 1144  
 Gender: Female  
 Accession #: 00001144-BLD  
 Requisition #: 000000

ORDERING PHYSICIAN: **Physician Name, MD**

**RESULT: POSITIVE—CLINICALLY SIGNIFICANT MUTATION IDENTIFIED**

Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

| GENE  | MUTATION                                     | INTERPRETATION  |
|-------|--|---|
| BRCA1 | c.68_69del (p.Glu23Valfs*17)<br>Heterozygous | <b>HIGH CANCER RISK</b><br>This patient has Hereditary Breast and Ovarian Cancer (HBOC) syndrome. |

DETAILS ABOUT: BRCA1 c.68\_69del (p.Glu23Valfs\*17); NM\_007294.3; AKA: 187delAG

**Functional Significance: Deleterious - Abnormal Protein Production and/or Function**  
 The heterozygous germline BRCA1 mutation c.68\_69del is predicted to result in the premature truncation of the BRCA1 protein at amino acid position 39 (p.Glu23Valfs\*17).

**Clinical Significance: High Cancer Risk**  
 This mutation is associated with increased cancer risk and should be regarded as clinically significant.

**ADDITIONAL FINDINGS: VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED**

| GENE              | VARIANT(S) OF UNCERTAIN SIGNIFICANCE | INTERPRETATION  |
|-------------------|--------------------------------------|---|
| CDKN2A (p16INK4a) | c.2T>A                               | <b>UNCERTAIN CLINICAL SIGNIFICANCE</b><br>There are currently insufficient data to determine if these variants cause increased cancer risk. |

**Additional Details About CDKN2A (p16INK4a):** The heterozygous germline CDKN2A (p16INK4a) variant c.2T>A is located within the CDKN2A (p16INK4a) gene translation start codon and is predicted to result in abnormal protein translation. Start codon mutations are known to disrupt normal initiation of protein synthesis and are interpreted as pathogenic according to the recommendations of the American College of Medical Genetics (Richards CS et al. Genet Med. 10:294-300, 2008). However, an alternative in-frame methionine is located 9 amino acids downstream of the normal start codon. If this methionine were to be utilized as an alternative initiation codon, it would result in the deletion of the first 8 amino acids of the CDKN2A (p16INK4a) protein. At this time, there is insufficient information to determine whether or not this alternative methionine is utilized, and if the resulting shortened protein would be fully functional.

**Details About Non-Clinically Significant Variants:** All individuals carry DNA changes (i.e., variants) and most variants do not increase an individual's risk of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign variants (Favor Polymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most likely do not cause increased cancer risk. Present evidence does not suggest that non-clinically significant variant findings be used to modify patient medical management beyond what is indicated by the personal and family history and any other significant clinical findings.

**Variant Classification:** Myriad's myVision™ Variant Reclassification Program continuously performs ongoing evaluations of variant classifications. In certain cases, healthcare providers may be contacted for more clinical information or to arrange family testing to aid in variant classification. When new evidence about a variant is identified and determined to result in clinical significance and management change, that information will automatically be made available to the healthcare provider through an amended report.

MYRIAD, © 2014, Myriad Genetics Laboratories, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 800-488-7423 FX: 801-584-3015 myRisk Genetic Result Page 1 of 2

MYRIAD, © 2014, Myriad Genetics Laboratories, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 800-488-7423 FX: 801-584-3015 myRisk Genetic Result Page 1 of 1

The genetic test result

The genetic test result indicates whether a clinically actionable mutation is identified from the 25 genes analyzed.

If positive, the genetic mutation is detailed with appropriate nomenclature, and its clinical and functional significance.


Presence of genetic variants of uncertain significance (VUS) that are not currently considered clinically actionable, are reported.





# Impact of Positive Test on the Family

- Blood related relatives should be offered genetic testing due to medical management recommendations (i.e. cascade testing)
- Majority of at-risk relatives may not know of risk and of those who do uptake of testing occurs in <50%
- Barriers cited in the literature include lack of family communication, lack of closeness to specific family members; lack of knowledge of how to communicate genetic testing results; access to testing



# Genetic discrimination



- Genetic Information Non-Discrimination Act (GINA) 2008
- GINA protects individuals against workplace or insurance discrimination connected to genetic information in an individual or family. The law does not cover military, life, long-term, or disability insurance.
- States have laws that protect individuals' and families' genetic information, and practitioners should be aware of protections unique to the patient population served.

Underhill-Blazey, M. L. & Khlem, M. (2020). Genetic Discrimination: The Genetic Information Nondiscrimination Act's Impact on Practice and Research. *Clinical Journal of Oncology Nursing* Number 2/April 2020, 24(2), 135-137.





---

## Insurance coverage and cost

- For eligible individuals insurance typically covers genetic testing.
  - There may be a co-pay for the counseling visit
  - May have a deductible
- For those who are uninsured, laboratories have financial assistance plans
  - May be a cost for counseling visit



# The role of inherited genetic information in cancer care

- Hereditary cancer care is focused on the **individual** and **family** and is relevant across the spectrum of cancer care.
  - **Prevention:** lifestyle, medication, surgery
    - Chemoprevention; prophylactic organ removal; lifestyle
  - **Early detection:** high risk screening/surveillance
    - Breast MRI; EUS pancreas
  - **Treatment:** targeted therapies
    - PARP Inhibitors in ovarian cancer; pancreatic cancer
  - **End-of-life:** family implications; caregiving support for at-risk relatives



(Daly et al, 2016; Gues et al, 2016)

20





This leads to multiple health decisions...



# What actions are taken based on results?




## Cancer Prevention & Risk Reduction

Healthy lifestyle changes  
Chemoprevention  
Prophylactic surgeries



## Cancer Screening

Start at younger age  
More often  
More specific



## Target Therapy & Treatment Decisions

Surgical decision making  
Systemic treatment selection



# Pancreatic cancer as an example




Pancreatic Cancer Diagnosis



Targeted therapy

Pancreatic Cancer Surveillance

Live-Saving Surgery



# How does this make patients feel?



- Overall, genetic testing has not been shown to lead to **pathologic** anxiety or depression.
- However, the absence of pathology does not indicate that an individual does not have concern or perceive an impact of learning genetic results.
- Though anxiety and depression are not commonly associated with genetic testing results, higher risk perception, cancer worry, and uncertainty do occur, especially in those with a positive genetic finding.





RESEARCH

Open Access

## Patient experiences living with pancreatic cancer risk

Meghan Underhill<sup>1\*</sup>, Donna Berry<sup>1</sup>, Emily Dalton<sup>2</sup>, Jaclyn Schienda<sup>1</sup> and Sapna Syngal<sup>1</sup>

### Abstract

**Background:** Pancreatic cancer (PancCa) is recognized as a component of many well-described hereditary cancer syndromes. Minimal research has focused on patient needs and experiences living with this risk.

**Purpose:** To understand the meaning and experience of living with familial PancCa risk and to explore experiences related to creating and executing of PancCa

Patient Education and Counseling 102 (2019) 1558–1564



Contents lists available at ScienceDirect  
Patient Education and Counseling

journal homepage: [www.elsevier.com/locate/pateducou](http://www.elsevier.com/locate/pateducou)



## Development and testing of the KnowGene scale to assess general cancer genetic knowledge related to multigene panel testing



Meghan Underhill-Blazey<sup>a</sup>, Jill Stopfer, Anu Chittenden, Manan M. Nayak, Kristina Lansang, Ruth Lederman, Judy Garber, Daniel A. Gundersen

<sup>a</sup>Dana-Farber Cancer Institute, Brigham and Women's Hospital, Simmons College, United States

## Seeking Balance: Decision Support Needs of Women Without Cancer and a Deleterious BRCA1 or BRCA2 Mutation

Meghan L. Underhill & Cheryl B. Crotser

BEHAVIORAL MEDICINE  
2016, VOL. 0, NO. 0, 1–9  
<http://dx.doi.org/10.1080/08964289.2016.1138925>



## Perceptions of Cancer Risk, Cause, and Needs in Participants from Low Socioeconomic Background at Risk for Hereditary Cancer

Meghan L. Underhill, PhD, RN, AOCNS<sup>a</sup>, Karleen R. Habin, RN, MSN<sup>b</sup>, and Kristen M. Shannon, MS, CGC<sup>c</sup>

<sup>a</sup>Dana-Farber Cancer Institute; <sup>b</sup>Massachusetts General Hospital, Cancer Resource Foundation; <sup>c</sup>Massachusetts General Hospital

## Cancer Medicine

Open Access

ORIGINAL RESEARCH

## A state-wide initiative to promote genetic testing in an underserved population

Meghan L. Underhill<sup>1</sup>, Traci M. Blonquist<sup>1</sup>, Karleen Habin<sup>2,3</sup>, Debra Lundquist<sup>1,5</sup>, Kristen Shannon<sup>4</sup>, Kathryn Robinson<sup>4</sup>, Mary-Lou Woodford<sup>4</sup> & Jean Bouchard<sup>1,1</sup>

<sup>1</sup>Dana-Farber Cancer Institute, 450 Brookline Ave 19522, Boston, Massachusetts, 02115

<sup>2</sup>Massachusetts General Hospital, Boston, MA, USA

<sup>3</sup>Boston College, Connell School of Nursing, Cancer Resource Foundation, Chestnut Hill, MA, USA

<sup>4</sup>School of Nursing, Northeastern University, Boston, MA, USA

<sup>5</sup>Cancer Resource Foundation, Marlborough, MA, USA

<sup>6</sup>Graduate School of Nursing, University of Massachusetts Medical School, Worcester, MA, USA



Meghan L. Underhill, PhD, RN, AOCNS  
Robin M. Lally, PhD, RN, AOCN  
Marc T. Kiviniemi, PhD  
Christine Muralayisani, MPH  
Suzanne S. Dickerson, DNS, RN

## Living My Family's Story

Identifying the Lived Experience in Healthy Women at Risk for Hereditary Breast Cancer

# Engaging in Medical Vigilance: Understanding the Personal Meaning of Breast Surveillance

Meghan L. Underhill, PhD, RN, AOCNS<sup>®</sup>, and Suzanne S. Dickerson, RN, DNS



Mutations in the *BRCA1* or *BRCA2* genes account for 80% of hereditary breast cancers. Women with those

**Purpose/Objectives:** To explore how hereditary risk of breast cancer experience managing that risk through surveillance

Received: 13 September 2017 | Revised: 27 February 2018 | Accepted: 9 March 2018  
DOI: 10.1002/poc.4712

PAPER

WILEY

## Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer

Meghan Underhill<sup>1</sup> | Fangxin Hong<sup>2</sup> | Janette Lawrence<sup>3</sup> | Traci Blonquist<sup>2</sup> | Sapna Syngal<sup>4,5</sup>

# Nursing Science is Critical to Understand Patient Experiences and to Improve Outcomes



SCHOOL OF  
NURSING  
UNIVERSITY OF ROCHESTER

# Summary of formative study findings

- **“Engaging in medical vigilance”**
  - Hereditary risk of breast cancer involves a change in one's view of life and necessitates engaging in medical vigilance, often making women feel ill when they are otherwise healthy (Underhill & Dickerson, 2011)
- **“Living my family's story”**
  - Healthy individuals living with risk approach risk within the context of the family cancer story, which impacts how they define themselves and engage in self-care (Underhill et al., 2012)
- **“Seeking balance”**
  - Living with hereditary breast and ovarian cancer risk is a dynamic and complex experience of balancing medical recommendations with personal and family values over time (Underhill & Crotser, 2013)
- **“Living with worry and uncertainty”**
  - Inherited cancer risk also leads to risk for more rare cancers such as pancreatic cancer, where the surveillance and prevention guidelines are still emerging. This can lead to fear and uncertainty, especially given the poor outcomes for people diagnosed with pancreatic cancer (Underhill-Blazey et al. 2015; Underhill-Blazey et al. 2018; Underhill-Blazey et al. 2020).



# Patient-Driven Findings



- *“I don’t worry about hypertension, I don’t worry about car crashes. I don’t worry about strokes. There’s a false positive that gets created, which is, you know, by being twelve or fourteen percent likely to die of pancreatic cancer you get it in your head you are going to die of pancreatic cancer. But the inverse, of course, that there is an 86% chance that you are going to die from something else. But for some reason that is not on my mind...”*
- -40 year-old male, father died of pancreatic cancer, BRCA2 mutation

Underhill M, Berry D, Dalton E, Schienda J, Syngal S. Patient experiences living with pancreatic cancer risk. *Hereditary Cancer in Clinical Practice*. 2015;13(1):13.




SCHOOL OF  
**NURSING**  
UNIVERSITY of ROCHESTER

# Interventions that are known to be effective...



MINDFULNESS BASED STRESS  
REDUCTION CAN IMPROVE  
PSYCHOSOCIAL AND PHYSICAL  
OUTCOMES FOR INDIVIDUALS AT HIGH  
RISK FOR CANCER DUE TO A KNOWN  
BRCA1/2 PATHOGENIC VARIANT



LIFESTYLE AND DIET INTERVENTIONS  
MAY HELP IMPROVE QUALITY OF LIFE IN  
PEOPLE WITH APC OR BRCA1/2




THEORY DRIVEN, FAMILY-BASED  
PSYCHOEDUCATION AND SKILLS  
INTERVENTIONS CAN IMPROVE  
COMMUNICATION, KNOWLEDGE, AND  
SOME PSYCHOSOCIAL OUTCOMES

# Summary

---

- The field of cancer genetics and prevention is rapidly evolving and a part of all of cancer care.
- Genetic testing can contribute to improve cancer prevention and early detection outcomes, as well as improved cancer treatment
- Genetic testing results can lead to a multitude of health decisions that can impact quality of life and may cause worry or uncertainty.
- Interventions that can support those living with high risk for cancer include psychoeducation; mindfulness; social support



# Cancer Screening and Prevention

**When thinking about inherited cancer risk it is important to not forget about the whole person!**

General population recommendations:

- All people undergo breast cancer risk assessment
- Mammogram starting at age 40 
- Colonoscopy starting at age 45
- 150 minutes a week of moderate to vigorous activity 
- Balanced diet to avoid obesity, minimize red meats & processed foods 
- Tobacco avoidance 
- Limit alcohol to <3 glasses a week 
- Vitamin D levels >30 for cancer prevention 
- Sleep and reduced stress are important for well-being! 



# Clinical Resources

---

Oncology Nursing Society: Genetics CNE

---

National Human Genome Research Institute:  
Genomics Competency

---

International Society of Nurses in Genetics

---

Jackson Labs: Cancer Genetics Clinical Education

---

National Comprehensive Cancer Network

---

Facing Our Risk for Cancer Empowered

---

Lynch Syndrome International

---

CDC: Family Health History

# Acknowledgements



- **Study team at UR:**

- Judy Brasch MS, RN
- Marian Moskow BS
- Eric Podsiadly BA
- Melanie Bobry MS, RN
- Charles Kamen MD, MPH
- Yingzi Zhang PhD, RN
- Sally Norton PhD, RN, FNAP, FPCN, FAAN
- WCI Hereditary Cancer Program
  - Ashley Hendershot DNP; Carol Lustig NP; Laura Kent RN
- Vivek Kaul, MD

*“If I have seen further than others, it is by standing upon the shoulders of giants.”*

-Isaac Newton

- **Relevant Funding sources:**

- URSON Research Support Grant; Daisy Foundation; UR Furth Fund; WCI Community Engagement Funding





# Select References

- Boucher, J., Roper, K., Underhill, M., & Berry, D. (2013). Science and practice aligned within nursing: Structure and process for evidence-based practice. *Journal of Nursing Administration*, 43(4), 229-234.
- Calzone, K. A., Jenkins, J., Bakos, A. D., Cashion, A. K., Donaldson, N., Feero, W. G., ... & Robinson, N. (2013). "A blueprint for genomic nursing science." *Journal of Nursing Scholarship*, 45(1): 96-104.
- Grady, P. A. (2017). Advancing Science, Improving Lives: NINR's New Strategic Plan and the Future of Nursing Science. *Journal of Nursing Scholarship*. 49(3): 247-248.
- Greco, K. E., Tinley, S., & Seibert, D. (2012). Essential genetic and genomic competencies for nurses with graduate degrees. ANA & ISONG. Retrieved on 3/28/2017. <http://www.nursingworld.org/MainMenuCategories/EthicsStandards/Resources/Genetics-1/Essential-Genetic-and-Genomic-Competencies-for-Nurses-With-Graduate-Degrees.pdf>
- Oncology Nursing Research Society (2016). ONS 2014-2018 Research Agenda. Retrieved on 3/28/2017. <https://www.ons.org/sites/default/files/2014-2018%20ONS%20Research%20Agenda.pdf>.
- Daly, M. B., et al. (2016). "Genetic/familial high-risk assessment: breast and ovarian, version 2.2015." *Journal of the National Comprehensive Cancer Network* 14(2): 153-162.
- Gopie, J. P., et al. (2012). "Surveillance for hereditary cancer: Does the benefit outweigh the psychological burden?—A systematic review." *Critical Reviews in Oncology/Hematology*.
- Gupta, S., et al. (2017). "NCCN guidelines insights: genetic/familial high-risk assessment: colorectal, version 3.2017." *Journal of the National Comprehensive Cancer Network* 15(12): 1465-1475.
- Lumish, H. S., et al. (2017). "Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients." *Journal of Genetic Counseling* 26(5): 1116-1129.
- Ringwald, J., et al. (2016). "Psychological Distress, Anxiety, and Depression of Cancer-Affected BRCA1/2 Mutation Carriers: a Systematic Review." *Journal of Genetic Counseling* 25(5): 880-891.
- Syngal, S., et al. (2015). "ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes." *Am J Gastroenterol* 110(2): 223-262; quiz 263.
- Tung, N., et al. (2016). "Counselling framework for moderate-penetrance cancer-susceptibility mutations." *Nature reviews Clinical oncology* 13(9): 581.
- Underhill, M., et al. (2015). "Patient experiences living with pancreatic cancer risk." *Hereditary cancer in clinical practice* 13(1): 13.
- Underhill, M., Habin, K., and Shannon, K. (2015). "Perceptions of cancer risk, cause, and needs in participants from low socioeconomic background at risk for hereditary cancer." *Behavioral Medicine* 43(4): 259-267.
- Underhill, M., et al. (2018). "Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer." *Psycho-Oncology* 27(7):1711-1718.
- Underhill, M. L. and C. B. Crotser (2014). "Seeking balance: decision support needs of women without cancer and a deleterious BRCA1 or BRCA2 mutation." *Journal of Genetic Counseling* 23(3): 350-362.
- Underhill, M. L. and S. S. Dickerson (2011). "Engaging in medical vigilance: understanding the personal meaning of breast surveillance." *Oncology nursing forum* 38(6): 686-694.
- Underhill, M. L., et al. (2012). "Living My Family's Story: Identifying the Lived Experience in Healthy Women at Risk for Hereditary Breast Cancer." *Cancer nursing* 35(6): 493-504  
410.1097/NCC.1090b1013e31824530fa.
- Underhill-Blazey, M., et al. (2019). "Development and testing of the KnowGene scale to assess general cancer genetic knowledge related to multigene panel testing." *Patient education and counseling* 102(8): 1558-1564.
- Vos, J., et al. (2013). "The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters." *Psychooncology* 22(4): 902-910.

# Thank You!





SCHOOL OF  
**NURSING**  
UNIVERSITY *of* ROCHESTER